Dose finding comparative study on levofloxacin (LVFX) in chronic respiratory tract infection

Atsushi Saito; Yuei Irabu; Hiroshi Fukuhara; Masakichi Motomiya; Akira Watanabe; Kotaro Oizumi; Hiroyuki Kobayashi; Hiroshi Oshitani; Koichiro Nakata; Yoshitaka Nakamori; Tatsuo Nakatani; Naohiko Chonabayashi; Fumio Matsumoto; Takeo Imai; Toshiyuki Yamamoto; Kanzo Suzuki; Kazuhide Yamamoto; Rinzo Soejima; Niro Okimoto; Yoshihisa Nakagawa; Masaru Sumi; Masaru Nasu; Hideaki Shigeno; Jun Goto; Hiroyuki Nagai; Toru Yamasaki; Kohei Hara; Yasumasa Doutsu; Naofumi Suyama; Hiroshi Tomita; Osamu Sakito; Keizo Matsumoto; Hirofumi Tanaka; Nobuya Ogawa; Keizo Yamaguchi; Keizo Yamaguchi

doi:10.11250/chemotherapy1953.40.Supplement3_75

Dose finding comparative study on levofloxacin (LVFX) in chronic respiratory tract infection

Atsushi Saito, Yuei Irabu, Hiroshi Fukuhara, Masakichi Motomiya, Akira Watanabe, Kotaro Oizumi, Hiroyuki Kobayashi, Hiroshi Oshitani, Koichiro Nakata, Yoshitaka Nakamori, Tatsuo Nakatani, Naohiko Chonabayashi, Fumio Matsumoto, Takeo Imai, Toshiyuki Yamamoto, Kanzo Suzuki, Kazuhide Yamamoto, Rinzo Soejima, Niro Okimoto, Yoshihisa NakagawaMasaru Sumi, Masaru Nasu, Hideaki Shigeno, Jun Goto, Hiroyuki Nagai, Toru Yamasaki, Kohei Hara, Yasumasa Doutsu, Naofumi Suyama, Hiroshi Tomita, Osamu Sakito, Keizo Matsumoto, Hirofumi Tanaka, Nobuya Ogawa, Keizo Yamaguchi, Keizo Yamaguchi

Research output: Contribution to journal › Article › peer-review

7 Citations (Scopus)

Abstract

A comparative clinical study on levofloxacin (LVFX, DR-3355) was conducted to determine the optimal dose of LVFX for treatment of chronic respiratory tract infections. Ofloxacin (OFLX) was used as the active control. LVFX at doses of 600 mg (200 mg t.i.d., LV600), and 300 mg (100 mg t.i.d., LV300) and OFLX at a dose of 600 mg (200 mg t.i.d., OF600) were allocated by the envelope randomization method and administered for 14 days as a rule. 1) The clinical efficacy rates, judged by the committee, were 71.4% (20/28) for the LV600 group, 76.0% (19/25) for the LV300 group and 82.6% (19/23) for the OF600 group. No significant differences were found among the three groups. 2) The elimination rates, based on the bacteriological efficacy, were 73.7% (14/19) in the LV600 group, 72.2% (13/18) in the LV300 group and 76.9% (10/13) in the OF600 group. No significant differences were found among three groups. 3) The incidences of side effects were 10.7% (3/28) in the LV600 group, 3.8% (1/26) in the LV300 group and 7.7% (2/26) in the OF600 group. The incidences of abnormal changes in the laboratory findings were 14.8% (4/27) in the LV600 group, 0% (0/25) in the LV300 group and 13.0% (3/23) in the OF600 group. No significant differences were found among the three groups. 4) The utility rates, judged by the committee, were 60.0% (15/25) for the LV600 group, 73.9% (17/23) for the LV300 group and 71.4% (15/21) for the OF600 group. When judged by the doctors in charge, the rates were 76.0% (19/25) for the LV600 group, 72.7% (16/22) for the LV300 group and 57.1% (12/21) for the OF600 group. No significant differences were found among the three groups. Based on these results, we surmise that a dose of 100 mg t.i.d. is the optimal dose of LVFX for the treatment of respiratory tract infections.

Original language	English
Pages (from-to)	75-96
Number of pages	22
Journal	Chemotherapy
Volume	40
DOIs	https://doi.org/10.11250/chemotherapy1953.40.Supplement3_75
Publication status	Published - 1992 May

Keywords

DR-3355
LVFX
Levofloxacin

ASJC Scopus subject areas

Pharmacology (medical)
Infectious Diseases
Pharmacology
Drug Discovery
Oncology

UN SDGs

This output contributes to the following UN Sustainable Development Goals (SDGs)

Access to Document

10.11250/chemotherapy1953.40.Supplement3_75

Cite this

Saito, A., Irabu, Y., Fukuhara, H., Motomiya, M., Watanabe, A., Oizumi, K., Kobayashi, H., Oshitani, H., Nakata, K., Nakamori, Y., Nakatani, T., Chonabayashi, N., Matsumoto, F., Imai, T., Yamamoto, T., Suzuki, K., Yamamoto, K., Soejima, R., Okimoto, N., ... Yamaguchi, K. (1992). Dose finding comparative study on levofloxacin (LVFX) in chronic respiratory tract infection. Chemotherapy, 40, 75-96. https://doi.org/10.11250/chemotherapy1953.40.Supplement3_75

Dose finding comparative study on levofloxacin (LVFX) in chronic respiratory tract infection. / Saito, Atsushi; Irabu, Yuei; Fukuhara, Hiroshi; Motomiya, Masakichi; Watanabe, Akira; Oizumi, Kotaro; Kobayashi, Hiroyuki; Oshitani, Hiroshi; Nakata, Koichiro; Nakamori, Yoshitaka; Nakatani, Tatsuo; Chonabayashi, Naohiko; Matsumoto, Fumio; Imai, Takeo; Yamamoto, Toshiyuki; Suzuki, Kanzo; Yamamoto, Kazuhide; Soejima, Rinzo; Okimoto, Niro; Nakagawa, Yoshihisa; Sumi, Masaru; Nasu, Masaru; Shigeno, Hideaki; Goto, Jun; Nagai, Hiroyuki; Yamasaki, Toru; Hara, Kohei; Doutsu, Yasumasa; Suyama, Naofumi; Tomita, Hiroshi; Sakito, Osamu; Matsumoto, Keizo; Tanaka, Hirofumi; Ogawa, Nobuya; Yamaguchi, Keizo; Yamaguchi, Keizo.

In: Chemotherapy, Vol. 40, 05.1992, p. 75-96.

Research output: Contribution to journal › Article › peer-review

Saito, A, Irabu, Y, Fukuhara, H, Motomiya, M, Watanabe, A, Oizumi, K, Kobayashi, H, Oshitani, H, Nakata, K, Nakamori, Y, Nakatani, T, Chonabayashi, N, Matsumoto, F, Imai, T, Yamamoto, T, Suzuki, K, Yamamoto, K, Soejima, R, Okimoto, N, Nakagawa, Y, Sumi, M, Nasu, M, Shigeno, H, Goto, J, Nagai, H, Yamasaki, T, Hara, K, Doutsu, Y, Suyama, N, Tomita, H, Sakito, O, Matsumoto, K, Tanaka, H, Ogawa, N, Yamaguchi, K & Yamaguchi, K 1992, 'Dose finding comparative study on levofloxacin (LVFX) in chronic respiratory tract infection', Chemotherapy, vol. 40, pp. 75-96. https://doi.org/10.11250/chemotherapy1953.40.Supplement3_75

Saito, Atsushi ; Irabu, Yuei ; Fukuhara, Hiroshi ; Motomiya, Masakichi ; Watanabe, Akira ; Oizumi, Kotaro ; Kobayashi, Hiroyuki ; Oshitani, Hiroshi ; Nakata, Koichiro ; Nakamori, Yoshitaka ; Nakatani, Tatsuo ; Chonabayashi, Naohiko ; Matsumoto, Fumio ; Imai, Takeo ; Yamamoto, Toshiyuki ; Suzuki, Kanzo ; Yamamoto, Kazuhide ; Soejima, Rinzo ; Okimoto, Niro ; Nakagawa, Yoshihisa ; Sumi, Masaru ; Nasu, Masaru ; Shigeno, Hideaki ; Goto, Jun ; Nagai, Hiroyuki ; Yamasaki, Toru ; Hara, Kohei ; Doutsu, Yasumasa ; Suyama, Naofumi ; Tomita, Hiroshi ; Sakito, Osamu ; Matsumoto, Keizo ; Tanaka, Hirofumi ; Ogawa, Nobuya ; Yamaguchi, Keizo ; Yamaguchi, Keizo. / Dose finding comparative study on levofloxacin (LVFX) in chronic respiratory tract infection. In: Chemotherapy. 1992 ; Vol. 40. pp. 75-96.

@article{85380c0d081447558e4de9c8c26d7f7c,

title = "Dose finding comparative study on levofloxacin (LVFX) in chronic respiratory tract infection",

abstract = "A comparative clinical study on levofloxacin (LVFX, DR-3355) was conducted to determine the optimal dose of LVFX for treatment of chronic respiratory tract infections. Ofloxacin (OFLX) was used as the active control. LVFX at doses of 600 mg (200 mg t.i.d., LV600), and 300 mg (100 mg t.i.d., LV300) and OFLX at a dose of 600 mg (200 mg t.i.d., OF600) were allocated by the envelope randomization method and administered for 14 days as a rule. 1) The clinical efficacy rates, judged by the committee, were 71.4% (20/28) for the LV600 group, 76.0% (19/25) for the LV300 group and 82.6% (19/23) for the OF600 group. No significant differences were found among the three groups. 2) The elimination rates, based on the bacteriological efficacy, were 73.7% (14/19) in the LV600 group, 72.2% (13/18) in the LV300 group and 76.9% (10/13) in the OF600 group. No significant differences were found among three groups. 3) The incidences of side effects were 10.7% (3/28) in the LV600 group, 3.8% (1/26) in the LV300 group and 7.7% (2/26) in the OF600 group. The incidences of abnormal changes in the laboratory findings were 14.8% (4/27) in the LV600 group, 0% (0/25) in the LV300 group and 13.0% (3/23) in the OF600 group. No significant differences were found among the three groups. 4) The utility rates, judged by the committee, were 60.0% (15/25) for the LV600 group, 73.9% (17/23) for the LV300 group and 71.4% (15/21) for the OF600 group. When judged by the doctors in charge, the rates were 76.0% (19/25) for the LV600 group, 72.7% (16/22) for the LV300 group and 57.1% (12/21) for the OF600 group. No significant differences were found among the three groups. Based on these results, we surmise that a dose of 100 mg t.i.d. is the optimal dose of LVFX for the treatment of respiratory tract infections.",

keywords = "DR-3355, LVFX, Levofloxacin",

author = "Atsushi Saito and Yuei Irabu and Hiroshi Fukuhara and Masakichi Motomiya and Akira Watanabe and Kotaro Oizumi and Hiroyuki Kobayashi and Hiroshi Oshitani and Koichiro Nakata and Yoshitaka Nakamori and Tatsuo Nakatani and Naohiko Chonabayashi and Fumio Matsumoto and Takeo Imai and Toshiyuki Yamamoto and Kanzo Suzuki and Kazuhide Yamamoto and Rinzo Soejima and Niro Okimoto and Yoshihisa Nakagawa and Masaru Sumi and Masaru Nasu and Hideaki Shigeno and Jun Goto and Hiroyuki Nagai and Toru Yamasaki and Kohei Hara and Yasumasa Doutsu and Naofumi Suyama and Hiroshi Tomita and Osamu Sakito and Keizo Matsumoto and Hirofumi Tanaka and Nobuya Ogawa and Keizo Yamaguchi and Keizo Yamaguchi",

year = "1992",

month = may,

doi = "10.11250/chemotherapy1953.40.Supplement3_75",

language = "English",

volume = "40",

pages = "75--96",

journal = "CHEMOTHERAPY",

issn = "0009-3165",

}

TY - JOUR

T1 - Dose finding comparative study on levofloxacin (LVFX) in chronic respiratory tract infection

AU - Saito, Atsushi

AU - Irabu, Yuei

AU - Fukuhara, Hiroshi

AU - Motomiya, Masakichi

AU - Watanabe, Akira

AU - Oizumi, Kotaro

AU - Kobayashi, Hiroyuki

AU - Oshitani, Hiroshi

AU - Nakata, Koichiro

AU - Nakamori, Yoshitaka

AU - Nakatani, Tatsuo

AU - Chonabayashi, Naohiko

AU - Matsumoto, Fumio

AU - Imai, Takeo

AU - Yamamoto, Toshiyuki

AU - Suzuki, Kanzo

AU - Yamamoto, Kazuhide

AU - Soejima, Rinzo

AU - Okimoto, Niro

AU - Nakagawa, Yoshihisa

AU - Sumi, Masaru

AU - Nasu, Masaru

AU - Shigeno, Hideaki

AU - Goto, Jun

AU - Nagai, Hiroyuki

AU - Yamasaki, Toru

AU - Hara, Kohei

AU - Doutsu, Yasumasa

AU - Suyama, Naofumi

AU - Tomita, Hiroshi

AU - Sakito, Osamu

AU - Matsumoto, Keizo

AU - Tanaka, Hirofumi

AU - Ogawa, Nobuya

AU - Yamaguchi, Keizo

PY - 1992/5

Y1 - 1992/5

N2 - A comparative clinical study on levofloxacin (LVFX, DR-3355) was conducted to determine the optimal dose of LVFX for treatment of chronic respiratory tract infections. Ofloxacin (OFLX) was used as the active control. LVFX at doses of 600 mg (200 mg t.i.d., LV600), and 300 mg (100 mg t.i.d., LV300) and OFLX at a dose of 600 mg (200 mg t.i.d., OF600) were allocated by the envelope randomization method and administered for 14 days as a rule. 1) The clinical efficacy rates, judged by the committee, were 71.4% (20/28) for the LV600 group, 76.0% (19/25) for the LV300 group and 82.6% (19/23) for the OF600 group. No significant differences were found among the three groups. 2) The elimination rates, based on the bacteriological efficacy, were 73.7% (14/19) in the LV600 group, 72.2% (13/18) in the LV300 group and 76.9% (10/13) in the OF600 group. No significant differences were found among three groups. 3) The incidences of side effects were 10.7% (3/28) in the LV600 group, 3.8% (1/26) in the LV300 group and 7.7% (2/26) in the OF600 group. The incidences of abnormal changes in the laboratory findings were 14.8% (4/27) in the LV600 group, 0% (0/25) in the LV300 group and 13.0% (3/23) in the OF600 group. No significant differences were found among the three groups. 4) The utility rates, judged by the committee, were 60.0% (15/25) for the LV600 group, 73.9% (17/23) for the LV300 group and 71.4% (15/21) for the OF600 group. When judged by the doctors in charge, the rates were 76.0% (19/25) for the LV600 group, 72.7% (16/22) for the LV300 group and 57.1% (12/21) for the OF600 group. No significant differences were found among the three groups. Based on these results, we surmise that a dose of 100 mg t.i.d. is the optimal dose of LVFX for the treatment of respiratory tract infections.

AB - A comparative clinical study on levofloxacin (LVFX, DR-3355) was conducted to determine the optimal dose of LVFX for treatment of chronic respiratory tract infections. Ofloxacin (OFLX) was used as the active control. LVFX at doses of 600 mg (200 mg t.i.d., LV600), and 300 mg (100 mg t.i.d., LV300) and OFLX at a dose of 600 mg (200 mg t.i.d., OF600) were allocated by the envelope randomization method and administered for 14 days as a rule. 1) The clinical efficacy rates, judged by the committee, were 71.4% (20/28) for the LV600 group, 76.0% (19/25) for the LV300 group and 82.6% (19/23) for the OF600 group. No significant differences were found among the three groups. 2) The elimination rates, based on the bacteriological efficacy, were 73.7% (14/19) in the LV600 group, 72.2% (13/18) in the LV300 group and 76.9% (10/13) in the OF600 group. No significant differences were found among three groups. 3) The incidences of side effects were 10.7% (3/28) in the LV600 group, 3.8% (1/26) in the LV300 group and 7.7% (2/26) in the OF600 group. The incidences of abnormal changes in the laboratory findings were 14.8% (4/27) in the LV600 group, 0% (0/25) in the LV300 group and 13.0% (3/23) in the OF600 group. No significant differences were found among the three groups. 4) The utility rates, judged by the committee, were 60.0% (15/25) for the LV600 group, 73.9% (17/23) for the LV300 group and 71.4% (15/21) for the OF600 group. When judged by the doctors in charge, the rates were 76.0% (19/25) for the LV600 group, 72.7% (16/22) for the LV300 group and 57.1% (12/21) for the OF600 group. No significant differences were found among the three groups. Based on these results, we surmise that a dose of 100 mg t.i.d. is the optimal dose of LVFX for the treatment of respiratory tract infections.

KW - DR-3355

KW - LVFX

KW - Levofloxacin

UR - http://www.scopus.com/inward/record.url?scp=0026696384&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=0026696384&partnerID=8YFLogxK

U2 - 10.11250/chemotherapy1953.40.Supplement3_75

DO - 10.11250/chemotherapy1953.40.Supplement3_75

M3 - Article

AN - SCOPUS:0026696384

VL - 40

SP - 75

EP - 96

JO - CHEMOTHERAPY

JF - CHEMOTHERAPY

SN - 0009-3165

ER -

Dose finding comparative study on levofloxacin (LVFX) in chronic respiratory tract infection

Abstract

Keywords

ASJC Scopus subject areas

UN SDGs

Access to Document

Other files and links

Fingerprint

Cite this